Darbepoetin is a recombinant DNA-produced protein related to erythropoietin. It stimulates erythropoiesis using the same mechanism as endogenous erythropoietin by interacting with progenitor stem cells to increase RBC production. Darbepoetin may be less immunogenic in animals than epoetin secondary to its formulation utilizing carbohydrates as part of its structure. Theoretically, carbohydrates may “shield” the sites on the drug of greatest antigenic potential from immune cell detection. Carbohydrates also increase the solubility and stability of the compound, causing less aggregate formation and, therefore, potentially less immunogenicity.
Darbepoetin may potentially be useful in treating anemia of chronic kidney disease in dogs and cats. It may be less immunogenic than epoetin, but this is only theoretical and has not been documented. Another advantage is that doses may be administered less often to maintain PCV. Treatment costs may be higher than using epoetin, however.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認精確活性成分與實際產品，不得把 epoetin、其他 ESA、內源性紅血球生成素、基因治療或輸血視為同義項。 分別確認物種、穩定 CKD 分期、貧血原因與嚴重度、臨床症狀、出血或溶血、骨髓疾病與近期輸血。 評估完整血球與網狀紅血球、血壓、鐵可用性與炎症限制、腎病變化、共病、免疫與腫瘤背景及所有共用治療。 由獸醫師建立個體化目標、採檢與追蹤時點、反應不足或失去反應的鑑別、PRCA 評估、調整、停藥與救援計畫。 確認所在地核准、供應、競賽與食用動物規範；沒有精確官方證據時保持未知。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
37%
21 hours